ZIVO — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2025-11-14

• our expectation that we will continue to incur operating losses and net cash outflows until such time we generate a level of revenue to support our cost structure;

• our intention to fund ongoing activities by utilizing our current cash on hand and by raising additional capital through equity and/or debt financings;

• our belief that if we are unable to raise sufficient additional capital, we may be compelled to reduce the scope of our operations and planned capital expenditures;

• our substantial doubt about our ability to continue as a going concern within one year after the date the financial statements are issued;

• as part of our therapeutic strategy, our expectation to continue to seek strategic partners for late-stage development, regulatory preparation and commercialization of our products in key global markets;

Text removed vs the prior filing · source: 10-Q · 2025-08-14

• our ability to continue as a going concern and our history of losses;

• our ability to prosecute, maintain or enforce our intellectual property rights;

• disputes or other developments relating to proprietary rights and claims of infringement;

• the accuracy of our estimates regarding expenses, future revenues and capital requirements;

• the implementation of our business model and strategic plans for our business and technology;